
Opus Genetics (IRD) Stock Forecast & Price Target
Opus Genetics (IRD) Analyst Ratings
Bulls say
Opus Genetics is a clinical-stage biopharmaceutical company with a strong pipeline of gene therapies targeting inherited retinal diseases. The recent positive clinical update for their lead program, OPGx-BEST1, has increased the probability of success and supports the potential for future success in their other programs. With an attractive valuation and potential for significant upside with upcoming milestones and new programs, Opus Genetics is a promising investment opportunity.
Bears say
Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing therapies for inherited retinal diseases and other retinal and refractive disorders. They operate in one segment and have a pipeline of seven AAV-based programs, with ongoing clinical trials for their lead programs OPGx-LCA5 and OPGx-BEST1. While the company has a revenue-generating product and is well-positioned in its development pipeline, there are risks to achieving target price due to uncertainties in clinical trials, regulatory approvals, and potential stock price volatility. Additionally, Opus Genetics' financials show that it has incurred significant losses and may require additional financing or partnerships in the future.
This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.
Opus Genetics (IRD) Analyst Forecast & Price Prediction
Start investing in Opus Genetics (IRD)
Order type
Buy in
Order amount
Est. shares
0 shares